Trial Profile
A study to evaluate the prognostic value of cetuximab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in patients with head and neck squamous cell carcinoma (HNSCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
- 18 Apr 2016 New trial record